Beneficial effects of treatment with transglutaminase inhibitor cystamine on macrophage response in NZB/W F1 mice

Experimental Biology and Medicine

Volumn 232, Issue 2, 2007, Pages 195-203

  Hsu, Tsai Ching ^a   Chiang, Szu Yi ^b   Huang, Chih Yang ^c   Tsay, Gregory J ^a,d   Yang, Chiao Wen ^a   Huang, Chien Ning ^d   Tzang, Bor Show ^a  

^a CHUNG SHAN MEDICAL UNIVERSITY   (Taiwan)

^b Hualien Hospital   (Taiwan)

^c CHINA MEDICAL UNIVERSITY   (Taiwan)

^d CHUNG SHAN MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

Cystamine; Matrix metalloproteinase (MMP); Systemic lupus erythematosus (SLE); Transglutaminase 2 (TG2)

Indexed keywords

CANCER GROWTH FACTOR; CARDIOLIPIN ANTIBODY; CYSTAMINE; GELATINASE B; MESSENGER RNA; PROTEIN GLUTAMINE GAMMA GLUTAMYLTRANSFERASE; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TISSUE INHIBITOR OF METALLOPROTEINASE 2; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL CELL; ARTICLE; DRUG EFFECT; ENZYME ACTIVITY; ENZYME INHIBITION; FEMALE; MACROPHAGE; MOUSE; NONHUMAN; PATHOGENESIS; PROTEIN EXPRESSION; SYSTEMIC LUPUS ERYTHEMATOSUS;

ANIMALS; ANTIBODIES, ANTICARDIOLIPIN; BASE SEQUENCE; CYSTAMINE; DNA PRIMERS; DOWN-REGULATION; ENZYME INHIBITORS; FEMALE; MACROPHAGES; MATRIX METALLOPROTEINASE 9; MICE; MICE, INBRED BALB C; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; TISSUE INHIBITOR OF METALLOPROTEINASE-1; TISSUE INHIBITOR OF METALLOPROTEINASE-2; TRANSFORMING GROWTH FACTOR BETA; TRANSGLUTAMINASES; TUMOR NECROSIS FACTOR-ALPHA;

MUS;

EID: 33846846255     PISSN: 15353702     EISSN: 15353699     Source Type: Journal    
DOI: None     Document Type: Article

References (43)

1. Hahn BH. An overview of the pathogenesis of systemic lupus erythematosus. In: Wallace DJ, Hahn BH, Eds. Dubois' Lupus Erythematosus. Philadelphia: Williams and Wilkins, pp69-76, 1993.
2. Winchester RJ. Systemic lupus erythematosus pathogenesis. In: Koopman WJ, Ed. Arthritis and Allied Conditions. Birmingham, AL: William and Wilkins, pp1361-1391, 1996.
3. Mok CC, Lau CS. Pathogenesis of systemic lupus erythematosus. J Clin Pathol 56:481-490, 2003.
4. Aringer M, Smolen JS. Cytokine expression in lupus kidneys. Lupus 14:13-18, 2005.
5. Gaipl US, Kuhn A, Sheriff A, Munoz LE, Franz S, Voll RE, Kalden JR, Herrmann M. Clearance of apoptotic cells in human SLE. Curr Dir Autoimmun 9:173-187, 2006.
6. Szondy Z, Sarang Z, Molnar P, Nemeth T, Piacentini M, Mastroberardino PG, Falasca L, Aeschlimann D, Kovacs J, Kiss I, Szegezdi F, Lakos G, Rajnavolgyi E, Birckbichler PJ, Melino G, Fesus L. Transglutaminase 2-/- mice reveal a phagocytosis-associated crosstalk between macrophages and apoptotic cells. Proc Natl Acad Sci U S A 100:7812-7817, 2003.
7. Pitidhammabhorn D, Kantachuvesiri S, Totemchokchyakarn K, Kitiyanant Y, Ubol S. Partial construction of apoptotic pathway in PBMC obtained from active SLE patients and the significance of plasma TNF-alpha on this pathway. Clin Rheumatol Jan 4:1-10, 2006.
8. Iismaa SE, Wu MJ, Nanda N, Church WB, Graham RM. GTP binding and signaling by Gh/transglutaminase II involves distinct residues in a unique GTP-binding pocket. J Biol Chem 275:18259-18265, 2000.
9. Singh US, Kunar MT, Kao YL, Baker KM. Role of transglutaminase II in retinoic acid-induced activation of RhoA-associated kinase-2. EMBO J 20:2413-2423, 2001.
10. Fesus L, Piacentini M. Transglutaminase 2: an enigmatic enzyme with diverse functions. Trends Biochem Sci 27:534-539, 2002.
11. Fesus L, Szondy Z. Transglutaminase 2 in the balance of cell death and survival. FEBS Lett 579:3297-3302, 2005.
12. Melino G, Annicchiarico-Petruzzelli M, Piredda L, Candi E, Gentile V, Davies PJ, Piacentini M. Tissue transglutaminase and apoptosis: sense and antisense transfection studies with human neuroblastoma cells. Mol Cell Biol 14:6584-6596, 1994.
13. Oliverio S, Amendola A, Rodolfo C, Spinedi A, Piacentini M. Inhibition of "tissue" transglutaminase increases cell survival by preventing apoptosis. J Biol Chem 274:34123-34128, 1999.
14. Falasca L, Iadevaia V, Ciccosanti F, Melino G, Serafino A, Piacentini M. Transglutaminase type II is a key element in the regulation of the anti-inflammatory response elicited by apoptotic cell engulfment. J Immunol 174:7330-7340, 2005.
15. Goetzl EJ, Banda MJ, Leppert D. Matrix metalloproteinases and immunity. J Immunol 156:1-4, 1996.
16. Faber-Elmann A, Sthoeger Z, Tcherniack A, Dayan M, Mozes E. Activity of matrix metalloproteinase-9 is elevated in sera of patients with systemic lupus erythematosus. Clin Exp Immunol 127:393-398, 2002.
17. Van Wart HE, Birkedal-Hansen H. The cysteine switch: a principle of regulation of metalloproteinase activity with potential applicability to the entire matrix metalloproteinase gene family. Proc Natl Acad Sci U S A 87:5578-5582, 1990.
18. Ramos-DeSimone N, Hahn-Dantona E, Sipley J, Nagase H, French DL, Quigley JP. Activation of matrix metalloproteinase-9 (MMP-9) via a converging plasmin/stromelysin-1 cascade enhances tumor cell invasion. J Biol Chem 274:13066-13076, 1999.
19. Vu TH, Werb Z. Matrix metalloproteinases: effectors of development and normal physiology. Genes Dev 14:2123-2133, 2000.
20. Opdenaker G, Van der Steen PE, Van Damme J. Gelatinase B. A turner and amplifier of immune functions. Trends Immunol 22:571-579, 2001.
21. Folk JE. Transglutaminases. Annu Rev Biochem 49:517-531, 1980.
22. Lorand L, Conrad SM. Transglutaminases. Mol Cell Biochem 58:9-35, 1984.
23. Brew K, Dinakarpandian D, Nagase H. Tissue inhibitors of metalloproteinases: evolution, structure and function. Biochim Biophys Acta 1477:267-283, 2000.
24. Jeitner TM, Delikatny EJ, Ahlqvist J, Capper H, Cooper AJ. Mechanism for the inhibition of transglutaminase 2 by cystamine. Biochem Pharmacol 69:961-970, 2005.
25. Saber-Lichtenberg Y, Brix K, Schmitz A, Heuser JE, Wilson JH, Lorand L, Herzog V. Covalent cross-linking of secreted bovine thyroglobulin by transglutaminase. FASEB J 14:1005-1014, 2000.
26. Lesort M, Lee M, Tucholski J, Johnson GV. Cystamine inhibits caspase activity. Implications for the treatment of polyglutamine disorders. J Biol Chem 278:3825-3830, 2003.
27. Karpuj MV, Becher MW, Springer JE, Chabas D, Youssef S, Pedotti R, Mitchell D, Steinman L. Prolonged survival and decreased abnormal movements in transgenic model of Huntington disease, with administration of the transglutaminase inhibitor cystamine. Nat Med 8:143-149, 2002.
28. Muhlradt PF, Frisch M. Purification and partial biochemical characterization of a Mycoplasma fermentans-derived substance that activates macrophages to release nitric oxide, tumor necrosis factor, and interleukin-6. Infect Immun 62:3801-3807, 1994.
29. Slaughter TF, Achyuthan KE, Lai TS, Greenberg CS. A microtiter plate transglutaminase assay utilizing 5-(biotinamido) pentylamine as substrate. Anal Biochem 205:166-171, 1992.
30. Laemmli UK. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 227:680-684, 1970.
31. Liu Z, Shipley JM, Vu TH, Zhou X, Diaz LA, Werb Z, Senior RM. Gelatinase B-deficient mice are resistant to experimental bullous pemphigoid. J Exp Med 188:475-482, 1998.
32. Creange A, Sharshar T, Planchenault T, Christory C, Poron F, Raphael JC, Gherardi RK. Matrix metalloproteinase-9 is increased and correlates with severity in Guillain-Barre syndrome. Neurology 53:1683-1691, 1999.
33. Ozenci V, Rinaldi L, Teleshova N, Matusevicius D, Kivisakk P, Kouwenhoven M, Link H. Metalloproteinases and their tissue inhibitors in multiple sclerosis. J Autoimmun 12:297-303, 1999.
34. Segal R, Bermas BL, Dayan M, Kalush F, Shearer GM, Mozes F. Kinetics of cytokine production in experimental systemic lupus erythematosus: involvement of T helper cell 1/T helper cell 2-type cytokines in disease. J Immunol 158:3009-3016, 1997.
35. Dean GS, Tyrrell-Price J, Crawley E, Isenberg DA. Cytokines and systemic lupus erythematosus. Ann Rheum Dis 59:243-251, 2000.
36. Van Raamsdonk JM, Pearson J, Bailey CD, Rogers DA, Johnson GV, Hayden MR, Leavitt BR. Cystamine treatment is neuroprotective in the YAC128 mouse model of Huntington disease. J Neurochem 95:210-220, 2005.
37. Stephens P, Grenard P, Aeschlimann P, Langley M, Blain E, Errington R, Kipling D, Thomas D, Aeschlimann D. Crosslinking and G-protein functions of transglutaminase 2 contribute differentially to fibroblast wound healing responses. J Cell Sci 117:3389-3403, 2004.
38. Cvetanovic M, Ucker DS. Innate immune discrimination of apoptotic cells: repression of proinflammatory macrophage transcription is coupled directly to specific recognition. J Immunol 172:880-889, 2004.
39. Mok CC, Lau CS. Pathogenesis of systemic lupus erythematosus. J Clin Pathol 56:481-490, 2003.
40. Nagy G, Koncz A, Perl A. T- and B-cell abnormalities in systemic lupus erythematosus. Crit Rev Immunol 25:123-140, 2005.
41. Tsuzaka K, Setoyama Y, Yoshimoto K, Shiraishi K, Suzuki K, Abe T, Takeuchi T. A splice variant of the TCR zeta mRNA lacking exon 7 leads to the down-regulation of TCR zeta, the TCR/CD3 complex, and IL-2 production in systemic lupus erythematosus T cells. J Immunol 174:3518-3525, 2005.
42. Potter PK, Cortes-Hernandez J, Quartier P, Botto M, Walport MJ. Lupus-prone mice have an abnormal response to thioglycolate and an impaired clearance of apoptotic cells. J Immunol 170:3223-3232, 2003.
43. Fox JH, Barber DS, Singh B, Zucker B, Swindell MK, Norflus F, Buzescu R, Chopra R, Ferrante RJ, Kazantsev A, Hersch SM. Cystamine increases L-cysteine levels in Huntington's disease transgenic mouse brain and in a PC12 model of polyglutamine aggregation. J Neurochem 91:413-442, 2004.